Kiniksa Pharmaceuticals Ltd

KNSA71

High Growth

$22.27arrow_drop_down1.54%-$0.35

High Growth

KNSA71

$22.27

arrow_drop_down1.54%-$0.35

High Growth

Performance History

Key Stats
Open	$23.18
Prev. Close	$22.99
EPS	-0.12
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	22.56	24.33
52 Week Range	14.12	28.52

Ratios







EPS	-0.12

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Kiniksa Pharmaceuticals Ltd (KNSA)

The stock price history of Kiniksa Pharmaceuticals Ltd (KNSA) has shown significant variability over the years. The company went public in 2018 with an initial offering price of $18 per share. Initially, the stock price performed well, reaching a high of $35 in the first few months. However, it faced a downward trend in the following months, dropping to around $10 by the end of the year. The stock continued to experience volatility in the subsequent years, with occasional spikes and dips.

As of the most recent quote, Kiniksa Pharmaceuticals Ltd (KNSA) is trading at $26 per share. The stock has shown resilience amidst the ongoing market uncertainties. Analysts are optimistic about the company's prospects, as it focuses on developing novel therapies for inflammatory diseases and other medical conditions. The recent positive news regarding the progress of their clinical trials has attracted investor attention and contributed to the upward movement in stock price.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Sanj K. Patel
Headquarters: Hamilton
Employees: 220
Exchange: NASDAQ

add Kiniksa Pharmaceuticals Ltd to watchlist

Keep an eye on Kiniksa Pharmaceuticals Ltd

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Kiniksa Pharmaceuticals Ltd's (KNSA) price per share?

The current price per share for Kiniksa Pharmaceuticals Ltd (KNSA) is $22.27. The stock has seen a price change of -$0.35 recently, indicating a -1.55% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Kiniksa Pharmaceuticals Ltd (KNSA)?

For Kiniksa Pharmaceuticals Ltd (KNSA), the 52-week high is $28.52, which is 28.06% from the current price. The 52-week low is $14.12, the current price is 57.72% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Kiniksa Pharmaceuticals Ltd (KNSA) a growth stock?

Kiniksa Pharmaceuticals Ltd (KNSA) has shown an average price growth of -3.55% over the past three years. It has received a score of 76 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Kiniksa Pharmaceuticals Ltd as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Kiniksa Pharmaceuticals Ltd (KNSA) stock price performance year to date (YTD)?

As of the latest data, Kiniksa Pharmaceuticals Ltd (KNSA) has a year-to-date price change of 20.18%. Over the past month, the stock has experienced a price change of -16.37%. Over the last three months, the change has been -13.41%. Over the past six months, the figure is 13.74%. Looking at a longer horizon, the five-year price change stands at 235.9%.

help

Is Kiniksa Pharmaceuticals Ltd (KNSA) a profitable company?

Kiniksa Pharmaceuticals Ltd (KNSA) has a net income of $14.08M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 66.31% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -8.61% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $270.26M, with a revenue growth rate of 22.74%, providing insight into the company's sales performance and growth. The gross profit is $179.22M. Operating income is noted at -$25.2M. Furthermore, the EBITDA is -$24.4M.

help

What is the market capitalization of Kiniksa Pharmaceuticals Ltd (KNSA)?

Kiniksa Pharmaceuticals Ltd (KNSA) has a market capitalization of $1.61B. The average daily trading volume is 22.48, indicating the stock's liquidity and investor engagement.